These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 33153146)
1. Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors. Keretsu S; Ghosh S; Cho SJ Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153146 [TBL] [Abstract][Full Text] [Related]
2. Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs). Lu Y; Mao F; Li X; Zheng X; Wang M; Xu Q; Zhu J; Li J J Med Chem; 2017 Jun; 60(12):5099-5119. PubMed ID: 28541695 [TBL] [Abstract][Full Text] [Related]
3. Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors. Kettle JG; Anjum R; Barry E; Bhavsar D; Brown C; Boyd S; Campbell A; Goldberg K; Grondine M; Guichard S; Hardy CJ; Hunt T; Jones RDO; Li X; Moleva O; Ogg D; Overman RC; Packer MJ; Pearson S; Schimpl M; Shao W; Smith A; Smith JM; Stead D; Stokes S; Tucker M; Ye Y J Med Chem; 2018 Oct; 61(19):8797-8810. PubMed ID: 30204441 [TBL] [Abstract][Full Text] [Related]
4. Proteogenomics for the Study of Gastrointestinal Stromal Tumors. Kondo T Adv Exp Med Biol; 2016; 926():139-151. PubMed ID: 27686810 [TBL] [Abstract][Full Text] [Related]
5. Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)- Wu Y; Wang B; Wang J; Qi S; Zou F; Qi Z; Liu F; Liu Q; Chen C; Hu C; Hu Z; Wang A; Wang L; Wang W; Ren T; Cai Y; Bai M; Liu Q; Liu J J Med Chem; 2019 Jul; 62(13):6083-6101. PubMed ID: 31250638 [TBL] [Abstract][Full Text] [Related]
6. Advances in Drug Therapy for Gastrointestinal Stromal Tumour. Liu J; Li J; Zhu Y; Jing R; Ding S; Zhang J; Zhao L; Chen Y; Shen J Curr Med Chem; 2024; 31(21):3057-3073. PubMed ID: 37151058 [TBL] [Abstract][Full Text] [Related]
7. Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFRα mutation in a metastatic GIST patient responding to imatinib. Nannini M; Tarantino G; Indio V; Ravegnini G; Astolfi A; Urbini M; De Leo A; Santini D; Ceccarelli C; Gruppioni E; Altimari A; Castellucci P; Fanti S; Di Scioscio V; Saponara M; Gatto L; Pession A; Martelli PL; Casadio R; Pantaleo MA Sci Rep; 2019 Feb; 9(1):2172. PubMed ID: 30778083 [TBL] [Abstract][Full Text] [Related]
8. Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors. Banks E; Grondine M; Bhavsar D; Barry E; Kettle JG; Reddy VP; Brown C; Wang H; Mettetal JT; Collins T; Adeyemi O; Overman R; Lawson D; Harmer AR; Reimer C; Drew L; Packer MJ; Cosulich S; Jones RD; Shao W; Wilson D; Guichard S; Fawell S; Anjum R Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32350132 [TBL] [Abstract][Full Text] [Related]
9. Discovery of ( E)- N Liu X; Wang B; Chen C; Qi Z; Zou F; Wang J; Hu C; Wang A; Ge J; Liu Q; Yu K; Hu Z; Jiang Z; Wang W; Wang L; Wang W; Ren T; Bai M; Liu Q; Liu J J Med Chem; 2019 May; 62(10):5006-5024. PubMed ID: 31046271 [TBL] [Abstract][Full Text] [Related]
10. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Burger H; den Bakker MA; Kros JM; van Tol H; de Bruin AM; Oosterhuis W; van den Ingh HF; van der Harst E; de Schipper HP; Wiemer EA; Nooter K Cancer Biol Ther; 2005 Nov; 4(11):1270-4. PubMed ID: 16294026 [TBL] [Abstract][Full Text] [Related]
15. Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia. Lin WH; Wu SY; Yeh TK; Chen CT; Song JS; Shiao HY; Kuo CC; Hsu T; Lu CT; Wang PC; Wu TS; Peng YH; Lin HY; Chen CP; Weng YL; Kung FC; Wu MH; Su YC; Huang KW; Chou LH; Hsueh CC; Yen KJ; Kuo PC; Huang CL; Chen LT; Shih C; Tsai HJ; Jiaang WT J Med Chem; 2019 Dec; 62(24):11135-11150. PubMed ID: 31721578 [TBL] [Abstract][Full Text] [Related]
16. [Molecular and genetic features of gastrointestinal stromal tumors (GIST)]. Buleje S J; Yábar B A; Guevara-Fujita M; Fujita R Rev Gastroenterol Peru; 2012; 32(4):394-9. PubMed ID: 23307090 [TBL] [Abstract][Full Text] [Related]
17. Computational investigation of imidazo[2,1-b]oxazole derivatives as potential mutant BRAF kinase inhibitors: 3D-QSAR, molecular docking, molecular dynamics simulation, and ADMETox studies. Boutalaka M; El Bahi S; Alaqarbeh M; El Alaouy MA; Koubi Y; Khatabi KE; Maghat H; Bouachrine M; Lakhlifi T J Biomol Struct Dyn; 2024 Jul; 42(10):5268-5287. PubMed ID: 37424193 [TBL] [Abstract][Full Text] [Related]
18. Receptor tyrosine kinase kit and gastrointestinal stromal tumours: an overview. Sartini S; Dario B; Morelli M; Da Settimo F; La Motta C Curr Med Chem; 2011; 18(19):2893-903. PubMed ID: 21651490 [TBL] [Abstract][Full Text] [Related]
19. [Gastrointestinal stromal tumors carrying PDGFRalpha mutations occur preferentially in the stomach and exhibit an epithelioid or mixed phenotype]. Wardelmann E; Pauls K; Merkelbach-Bruse S; Hrychyk A; Losen I; Hohenberger P; Büttner R; Pietsch T Verh Dtsch Ges Pathol; 2004; 88():174-83. PubMed ID: 16892550 [TBL] [Abstract][Full Text] [Related]
20. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors]. Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]